Frost & Sullivan Award Highlights the Immense Potential of Radisens's Integrated Point-of-Care Diagnostic Platform

Frost & Sullivan Award Highlights the Immense Potential of Radisens's Integrated Point-of-Care Diagnostic Platform PR Newswire LONDON, Nov. 29, 2012 - Radisens's single connected multi-diagnostic device represents a highly effective tool to combat rising chronic disease management costs LONDON, Nov. 29, 2012 /PRNewswire/ -- Based on its recent analysis of the integrated point-of-care (POC) diagnostic platforms market, Frost & Sullivan recognises Radisens Diagnostics Limited with the 2012 European Technology Innovation Award. Realising the onward surge to integrate POC instruments covering multiple blood test categories, Radisens is developing a single connected multi-diagnostic device, based on its proprietary technology, for long-term chronic disease management. "Radisens's miniaturised POC device and consumable platform integrates different combinations of multiplexed high- sensitivity immunoassays, clinical chemistries, and haematology (cell counting) assays onto single consumable panels," explained Frost & Sullivan Healthcare Industry Analyst Prasanna Vadhana Kannan. "These panels initially target long- term chronic disease management of thyroid disorders, chronic diabetes, cardiovascular disease, chronic kidney disease, and cell counting." This single device thereby effectively replaces the ten to fifteen stand-alone instruments that a physician would typically require for routine blood testing. Moreover, the interpretation of lab-grade data is instantaneous.